Chimeric Antigen Receptor Therapy for B-cell Malignancies

We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients.

Detalles Bibliográficos
Autores principales: Porter, David L, Kalos, Michael, Zheng, Zhaohui, Levine, Bruce, June, Carl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119397/
https://www.ncbi.nlm.nih.gov/pubmed/21716851
_version_ 1782206564409540608
author Porter, David L
Kalos, Michael
Zheng, Zhaohui
Levine, Bruce
June, Carl
author_facet Porter, David L
Kalos, Michael
Zheng, Zhaohui
Levine, Bruce
June, Carl
author_sort Porter, David L
collection PubMed
description We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients.
format Online
Article
Text
id pubmed-3119397
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-31193972011-06-28 Chimeric Antigen Receptor Therapy for B-cell Malignancies Porter, David L Kalos, Michael Zheng, Zhaohui Levine, Bruce June, Carl J Cancer Short Report We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients. Ivyspring International Publisher 2011-06-01 /pmc/articles/PMC3119397/ /pubmed/21716851 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Short Report
Porter, David L
Kalos, Michael
Zheng, Zhaohui
Levine, Bruce
June, Carl
Chimeric Antigen Receptor Therapy for B-cell Malignancies
title Chimeric Antigen Receptor Therapy for B-cell Malignancies
title_full Chimeric Antigen Receptor Therapy for B-cell Malignancies
title_fullStr Chimeric Antigen Receptor Therapy for B-cell Malignancies
title_full_unstemmed Chimeric Antigen Receptor Therapy for B-cell Malignancies
title_short Chimeric Antigen Receptor Therapy for B-cell Malignancies
title_sort chimeric antigen receptor therapy for b-cell malignancies
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119397/
https://www.ncbi.nlm.nih.gov/pubmed/21716851
work_keys_str_mv AT porterdavidl chimericantigenreceptortherapyforbcellmalignancies
AT kalosmichael chimericantigenreceptortherapyforbcellmalignancies
AT zhengzhaohui chimericantigenreceptortherapyforbcellmalignancies
AT levinebruce chimericantigenreceptortherapyforbcellmalignancies
AT junecarl chimericantigenreceptortherapyforbcellmalignancies

Ejemplares similares